Travere Therapeutics, Inc.
TVTX
Kedudukan dalam Saham
#3577
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies... Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Harga Saham
$50.52
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$4.76B
Perubahan (1 hari)
1.85%
Perubahan (1 tahun)
81.14%
Negara
US
Perdagangan Travere Therapeutics, Inc. (TVTX)
Kategori
Healthcare
Pendapatan untuk Travere Therapeutics, Inc. (TVTX)
Pendapatan pada Jun 2026 TTM: $-67.07M
Menurut laporan kewangan terkini Travere Therapeutics, Inc., pendapatan semasa syarikat ialah $-67.07M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-376.11M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-331.16M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Travere Therapeutics, Inc. dari 2009 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-67.07M | -79.07% |
| 2024 | $-320.51M | -14.78% |
| 2023 | $-376.11M | 13.58% |
| 2022 | $-331.16M | 52.69% |
| 2021 | $-216.88M | 14.88% |
| 2020 | $-188.79M | 28.91% |
| 2019 | $-146.45M | 43.76% |
| 2018 | $-101.87M | 74.54% |
| 2017 | $-58.36M | 1.36% |
| 2016 | $-57.58M | -154.60% |
| 2015 | $105.47M | -193.01% |
| 2014 | $-113.40M | 236.02% |
| 2013 | $-33.75M | 11.22% |
| 2012 | $-30.34M | 166,022.06% |
| 2009 | $-18.27K | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -7,964.30% |
US
|
|
| $-3.09B | 4,502.38% |
US
|
|
| $-4.02B | 5,887.71% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -3,008.21% |
NL
|
